A 2026 QNova LifeSciences Report
What You’ll Learn
Inside this whitepaper, you’ll discover:
- The key components of a successful U.S. FDA IND strategy
- Common challenges that delay IND submissions—and how to avoid them
- How CMC, nonclinical, and clinical development activities work together to support an IND
- Regulatory considerations that should begin well before submission
- Best practices for preparing documentation and supporting FDA review
- How experienced regulatory guidance can help reduce development risk and accelerate timelines
White Paper
Transitioning to a US FDA
IND as a Clinical-Stage Drug Company
Access the Complimentary Whitepaper
Preparing an Investigational New Drug (IND) application is one of the most important milestones in drug development. A successful IND submission requires much more than assembling regulatory documents—it demands a comprehensive strategy that integrates preclinical data, manufacturing, quality systems, clinical planning, and FDA expectations.
Whether you’re preparing your first IND or refining your regulatory strategy, this complimentary whitepaper from QNova LifeSciences provides practical guidance to help clinical-stage drug companies navigate the transition to a U.S. FDA IND with greater confidence.
Complete the form below to receive immediate access to your complimentary copy.
YOU MIGHT ALSO BE INTERESTED IN…
FDA QMSR Is Here: What Medical Device Companies Need to Know
Data and Safety Monitoring Board Best Practices in Clinical Trials
Trusted by medical device, biotech, and life sciences companies navigating complex FDA and quality system requirements.